Cargando…

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

Genetic heterogeneity contributes to clinical outcome and progression of most tumors. Yet, little is known regarding allelic diversity for epigenetic compartments and almost no data exists for acute myeloid leukemia (AML). Here we examined epigenetic heterogeneity as assessed by cytosine methylation...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Sheng, Garrett-Bakelman, Francine E., Chung, Stephen S., Sanders, Mathijs A., Hricik, Todd, Rapaport, Franck, Patel, Jay, Dillon, Richard, Vijay, Priyanka, Brown, Anna L., Perl, Alexander E., Cannon, Joy, Bullinger, Lars, Luger, Selina, Becker, Michael, Lewis, Ian D., To, Luen Bik, Delwel, Ruud, Löwenberg, Bob, Döhner, Hartmut, Döhner, Konstanze, Guzman, Monica L., Hassane, Duane C., Roboz, Gail J., Grimwade, David, Valk, Peter J.M., D’Andrea, Richard J., Carroll, Martin, Park, Christopher Y., Neuberg, Donna, Levine, Ross, Melnick, Ari M., Mason, Christopher E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938719/
https://www.ncbi.nlm.nih.gov/pubmed/27322744
http://dx.doi.org/10.1038/nm.4125
Descripción
Sumario:Genetic heterogeneity contributes to clinical outcome and progression of most tumors. Yet, little is known regarding allelic diversity for epigenetic compartments and almost no data exists for acute myeloid leukemia (AML). Here we examined epigenetic heterogeneity as assessed by cytosine methylation within defined genomic loci with four CpGs (epigenetic alleles), somatic mutations and transcriptomes of AML patient samples at serial time points. We observe that epigenetic allele burden is linked to inferior outcome and varies considerably during disease progression. Epigenetic and genetic allelic burden and patterning follow different patterns and kinetics during disease progression. We observed a subset of AMLs with high epiallele and low somatic mutation burden at diagnosis, a subset with high somatic mutation and lower epiallele burdens at diagnosis, and a subset with a mixed profile, suggesting distinct modes of tumor heterogeneity. Genes linked to promoter-associated epiallele shifts during tumor progression display increased single-cell transcriptional variance and differential expression, suggesting functional impact on gene regulation. Thus, genetic and epigenetic heterogeneity can occur with distinct kinetics, each likely able to impact biological and clinical features of tumors.